Researchers published comprehensive multi‑omic analyses following a genetically modified pig kidney transplanted into a brain‑dead human recipient and maintained for 61 days. Teams tracked tissue, blood and fluid samples at high temporal resolution to chart immune engagement and graft physiology, revealing that antibody and T‑cell responses jointly drove rejection episodes and that a cocktail of existing immunomodulators could reverse those reactions. The work, reported in Nature, profiled ~5,100 expressed human and pig genes within the graft and used longitudinal sampling to reconstruct day‑by‑day immune dynamics. Investigators identified specific immune cell types and pathways responsible for rejection and demonstrated pharmacologic control without permanent organ damage. Authors framed the data as a translational bridge to living‑patient xenotransplant trials, providing a roadmap to anticipate, detect, and manage immune reactions in future clinical applications. The studies emphasize the need for integrated immunosuppression regimens and real‑time molecular monitoring in xenotransplant development.